mitoxantrone has been researched along with Canine Diseases in 20 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol." | 9.22 | Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. ( Lee, JJ; Liao, AT; Wang, SL, 2016) |
| "Mitoxantrone was administered to 74 dogs with lymphoma at a dosage of 5." | 9.07 | Evaluation of mitoxantrone for the treatment of lymphoma in dogs. ( Cotter, SM; Dennis, RA; Getzy, DM; L'Heureux, DA; Moore, AS; Ogilvie, GK; Rand, WS; Ruslander, D, 1994) |
| "Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol." | 5.22 | Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. ( Lee, JJ; Liao, AT; Wang, SL, 2016) |
| "Mitoxantrone was administered to 74 dogs with lymphoma at a dosage of 5." | 5.07 | Evaluation of mitoxantrone for the treatment of lymphoma in dogs. ( Cotter, SM; Dennis, RA; Getzy, DM; L'Heureux, DA; Moore, AS; Ogilvie, GK; Rand, WS; Ruslander, D, 1994) |
| "Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response." | 2.80 | Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. ( Allstadt, SD; Boostrom, B; Rebhun, RB; Rodriguez, CO; Skorupski, KA, 2015) |
| " Ten dogs were given mitoxantrone at a dosage of 5." | 2.67 | Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study. ( Atwater, SW; Bergman, PJ; Chen, C; Ciekot, PA; Moore, AS; Ogilvie, GK; Walters, LM, 1994) |
| " Dogs underwent laser ablation of the primary tumor and were treated with mitoxantrone at a dosage of 5 mg/m2)every 3 weeks for 4 treatments." | 1.33 | Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma. ( Payton, ME; Tangner, CH; Upton, ML, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gedon, J | 1 |
| Kehl, A | 1 |
| Aupperle-Lellbach, H | 1 |
| von Bomhard, W | 1 |
| Schmidt, JM | 1 |
| Clerc-Renaud, B | 1 |
| Gieger, TL | 1 |
| LaRue, SM | 1 |
| Nolan, MW | 1 |
| Inkol, JM | 1 |
| Hocker, SE | 1 |
| Mutsaers, AJ | 1 |
| Kishimoto, TE | 1 |
| Yashima, S | 1 |
| Nakahira, R | 1 |
| Onozawa, E | 1 |
| Azakami, D | 1 |
| Ujike, M | 1 |
| Ochiai, K | 1 |
| Ishiwata, T | 1 |
| Takahashi, K | 1 |
| Michishita, M | 1 |
| Marquardt, TM | 1 |
| Lindley, SES | 1 |
| Smith, AN | 1 |
| Cannon, CM | 1 |
| Rodriguez, CO | 2 |
| Thamm, DH | 1 |
| Childress, MO | 1 |
| Northrup, NC | 1 |
| Kirsch, M | 1 |
| Weisse, C | 1 |
| Berent, A | 1 |
| Clifford, C | 1 |
| Leibman, N | 1 |
| Wittenburg, L | 1 |
| Solomon, SB | 1 |
| Lamb, K | 1 |
| Allstadt, SD | 1 |
| Boostrom, B | 1 |
| Rebhun, RB | 1 |
| Skorupski, KA | 1 |
| Wang, SL | 1 |
| Lee, JJ | 1 |
| Liao, AT | 1 |
| Arenas, C | 1 |
| Peña, L | 2 |
| Granados-Soler, JL | 1 |
| Pérez-Alenza, MD | 2 |
| Clemente, M | 1 |
| De Andrés, PJ | 1 |
| Daters, AT | 1 |
| Mauldin, GE | 1 |
| Mauldin, GN | 1 |
| Brodsky, EM | 1 |
| Post, GS | 1 |
| Spugnini, EP | 1 |
| Fanciulli, M | 1 |
| Citro, G | 1 |
| Baldi, A | 1 |
| Sicotte, V | 1 |
| Benamou, J | 1 |
| Fifle, LC | 1 |
| Planté, J | 1 |
| Lacoste, HI | 1 |
| Joly, H | 1 |
| Stern, AW | 1 |
| Upton, ML | 1 |
| Tangner, CH | 1 |
| Payton, ME | 1 |
| Ogilvie, GK | 5 |
| Moore, AS | 4 |
| Chen, C | 1 |
| Ciekot, PA | 1 |
| Atwater, SW | 1 |
| Bergman, PJ | 1 |
| Walters, LM | 2 |
| Ruslander, D | 1 |
| Rand, WS | 1 |
| Cotter, SM | 1 |
| Getzy, DM | 1 |
| L'Heureux, DA | 1 |
| Dennis, RA | 1 |
| Uno, Y | 1 |
| Momoi, Y | 1 |
| Watari, T | 1 |
| Goitsuka, R | 1 |
| Tsujimoto, H | 1 |
| Shimada, T | 1 |
| Ono, K | 1 |
| Goto, N | 1 |
| Hasegawa, A | 1 |
| Straw, RC | 3 |
| Jameson, VJ | 1 |
| Lafferty, MH | 1 |
| Powers, BE | 1 |
| Withrow, SJ | 3 |
| Obradovich, JE | 2 |
| Elmslie, RE | 2 |
| Vail, DM | 2 |
| Curtis, CR | 1 |
| Dickinson, K | 2 |
| Cooper, MF | 2 |
1 review available for mitoxantrone and Canine Diseases
| Article | Year |
|---|---|
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 2012 |
6 trials available for mitoxantrone and Canine Diseases
| Article | Year |
|---|---|
Pilot study comparing serum chemotherapy levels after intra-arterial and intravenous administration in dogs with naturally occurring urinary tract tumors.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carboplatin; Dog Diseases; Dogs; Female; Injection | 2019 |
Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Transitional Cell; Dog Diseases; Dogs; Drug | 2015 |
Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2016 |
Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Dog Disease | 2010 |
Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Topics: Animals; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Follow-Up Studies; Leukocyte Count; Logi | 1994 |
Evaluation of mitoxantrone for the treatment of lymphoma in dogs.
Topics: Animals; Dog Diseases; Dogs; Female; Lymphoma; Male; Mitoxantrone; Remission Induction | 1994 |
13 other studies available for mitoxantrone and Canine Diseases
| Article | Year |
|---|---|
BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019).
Topics: Animals; Carcinoma, Transitional Cell; Chlorambucil; Dog Diseases; Dogs; Female; Male; Meloxicam; Mi | 2022 |
Treatment of genitourinary carcinoma in dogs using nonsteroidal anti-inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Dog Diseases; | 2021 |
Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antineoplastic Combined Chemother | 2021 |
Identification of tumor-initiating cells derived from two canine rhabdomyosarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Drug Resistance, | 2017 |
Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2019 |
Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study.
Topics: 4-Butyrolactone; Animals; Antineoplastic Agents; Case-Control Studies; Chemotherapy, Adjuvant; Cyclo | 2016 |
Survival time of dogs with inflammatory mammary cancer treated with palliative therapy alone or palliative therapy plus chemotherapy.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; D | 2009 |
Use of surgery and mitoxantrone chemotherapy in a dog with disseminated lymphangiosarcoma.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Lymphangiosarcoma; Male; Mitoxantrone | 2012 |
Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carbon Dioxide; Carcinoma, Transitional Cell; Combined Modality Ther | 2006 |
Malignant histiocytosis with multiple skin lesions in a dog.
Topics: Animals; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Cycl | 1993 |
Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991).
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Dog Diseases; Dog | 1993 |
Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.
Topics: Animals; Anorexia; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Lymphoma; Male; Mitoxantrone; | 1991 |
Efficacy of mitoxantrone against various neoplasms in dogs.
Topics: Animals; Carcinoma; Dog Diseases; Dogs; Lymphoma; Mitoxantrone; Neoplasms; Prospective Studies; Remi | 1991 |